Last reviewed · How we verify

NCT06794190

Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants

Recruiting now Last updated 27 January 2025
What this trial tests

trial in Turner Syndrome in 120 participants. Currently enrolling.

Timeline
7 January 2025
Primary endpoint
6 January 2026
7 January 2026

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment120
Start date7 January 2025
Primary completion6 January 2026
Estimated completion7 January 2026
Sites1 location across Italy

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, female only, with Turner Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is therefore aimed at investigating the prevalence of hepatic alterations (laboratory and imaging) in adult patients with TS and generating hypothesissto the possible etiopathogenetic factors most involved, as well as evaluating the correlation between biochemical and structural abnormalities. Thus, the study could provide relevant etiopathogenetic and prognostic results on the development of hepatopathy in TS patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Turner Syndrome

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06794190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing